(Q83571290)
English
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III
scientific article published on 01 February 2012
Statements
Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial (English)
P P Tak
P J Mease
M C Genovese
J Kremer
B Haraoui
Y Tanaka
C O Bingham
A Ashrafzadeh
H Travers
S Safa-Leathers
S Kumar
1 February 2012